Bausch & Lomb vs National Vision
BLCO and EYE side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLCO and EYE compare
Bausch & Lomb is the larger company, worth 5.1 times as much as National Vision ($7.6B against $1.5B).
Bausch & Lomb grew revenue faster over the last twelve months (8.9% versus 7.0% for National Vision).
National Vision keeps more of each dollar of sales as profit, with a net margin of 3.2% compared with −2.0% at Bausch & Lomb.
National Vision scores higher on the StockData Score (13 against 9 for Bausch & Lomb), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLCO | EYE |
|---|---|---|
| Size and price | ||
| Market cap | $7.6B | $1.5B |
| Share price | $21.14 | $18.57 |
| Change, 1 year | 28.7% | −23.0% |
| Change, 5 years | – | −61.8% |
| Beta (5Y) | 0.76 | 0.97 |
| Employees | 13K | 13K |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 4 | 6 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.9× |
| P/S | 1.4× | 0.7× (better) |
| P/B | 1.2× (better) | 1.6× |
| EV/EBITDA | 15.4× | 8.3× (better) |
| P/FCF | 30.0× | 21.5× (better) |
| FCF yield | 3.3% | 4.6% (better) |
| Fair value | $28.91 | $30.42 |
| Margin of safety | 26.9% | 39.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | 7.0% |
| Revenue growth, 5Y average | 8.4% (better) | 3.0% |
| EPS growth, 5Y average | – | −3.4% |
| Profitability | ||
| Gross margin | – | 58.8% |
| Operating margin | 7.1% (better) | 5.1% |
| Net margin | −2.0% | 3.2% (better) |
| FCF margin | 4.7% (better) | 3.3% |
| Return on equity | −1.7% | 7.5% (better) |
| Return on invested capital | 2.8% | 7.2% (better) |
| Financial health | ||
| Debt / equity | 0.78 | 0.25 (better) |
| Net debt / EBITDA | 5.72 | 0.85 (better) |
| Interest coverage | 1.0× | – |
| Current ratio | 1.56 (better) | 0.63 |
| Altman Z-score | 1.08 | 2.13 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.6% |
| Shareholder yield | 0.00% | 3.6% (better) |
| Ownership | ||
| Held by institutions | 10.7% | 126% |
| Held by insiders | 0.81% | 2.5% |
| Insider net buying, 12 months | −$2.3M | −$498K (better) |
| Superinvestors holding | 4 (better) | 1 |
| Short interest, % of float | 0.73% | 21.3% |
Go deeper
- BLCO stock overview
- BLCO income statement
- BLCO valuation and score
- EYE stock overview
- EYE income statement
- EYE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.